High Glucose Induces Sumoylation of Smad4 via SUMO2/3 in Glomerular Mesangial Cells
Abstract
To investigate the expression of SUMO2/3 and Smad4 in rat glomerular mesangial cells (GMCs) induced by high glucose, and the interaction between small ubiquitin related modifier （SUMO）2/3 and Smad4; and to explore the role and mechanism of sumoylation in regulating TGF-β signaling in diabetic nephropathy. Methods Cultured rat GMCs were divided into five groups: normal glucose group (5.6 mmol/L glucose), high glucose groups (10, 20 and 30 mmol/L glucose), and mannitol group (osmotic control). The expression of SUMO2/3, Smad4 and fibronectin (FN) was measured by Western blot and RT-PCR. The interaction and colocalization between SUMO2/3 and Smad4 were detected by Co-immunoprecipitation and immunofluorescence confocal laser microscopy. Results Compared with controls, the expressions of SUMO2/3, Smad4 and FN in the cells in the high glucose groups increased (P<0.05). The co-immunoprecipitation and immunofluorescence confocal laser scanning showed that Smad4 interacted and colocalized with SUMO2/3 and the sumolyation (SUMO2/3) of Smad4 was enhanced significantly in the high glucose groups compared with the control group (P<0.05). Conclusion Sumolyation of Samd4 by SUMO2/3 may be involved in the regulation of TGF-β signaling in diabetic nephropathy.
Keywords: Diabetic nephropathy, Small ubiquitin related modifier, Smad4, Transforming growth factor-β, Co-immunoprecipitation
Full Text:
PDFReferences
Biernacka А, Dobaczewski M. Frangogiannis NG. TGF-£ signaling in fibrosis. Growth Factors,2011 ;29(5); 196-202.
Lan HY. Transforming growth factor-(3/Smad signalling in diabetic nephropathy. Clin Exp Pharmacol Physiol, 2012; 39 (8):731-738.
Yan D, Davis FJ, Sharrocks AD, et al. Emerging roles of SUMO modification in arthritis. Gene.2010;466( 12): 1-15.
Pohlers D, Brenmoehl J.Loffler I, el at. TGF-beta and fibrosis in different organs molecular pathway imprints. Biochim Biophys Acta,2009; 1792(8);746-756.
Lan HY. Diverse roles of TGF-beta/Smads in renal fibrosis and inflammation. Int J Biol Sci,2011;7(7): 1056-1067.
Kanauchi M, Nishioka H, Do hi K. Diagnostic significance of urinary fibronectin in diabetic nephropathy. Nihon Jinzo Gakkai Shi ,1995;37(2): 27-33.
Gao CL. Chen G, Liu L. et al. Impact of high glucose and proteasome inhibitor MG 132 on histone H2A and H2B ubiquitination in rat glomerular mesangial cells. J Diabetes Res*2013;2013:589474.
Andreou AM, Tavernarakis N. SUMOylation and cell signaling. Biotechnol J,2009;4( 12): 1740-1752.
Kang JS, Saunier EF, Akhurst RJ, et al. The type I TGF- beta receptor is covalently modified and regulated by sumoylation. Nat Cell Biol,2008; 10(6) :654-664.
Imoto S, Sugiyama K, Muromoto R, et al. Regulation of transforming growth factor-beta signaling by protein inhibitor of activated STAT PIASy through Smad3. J Biol Chem,2003; 278(36);34253-34258.
Lee PS. Chang C, Liu D, et al. Sumoylation of Smad4, the common Smad mediator of transforming growth factor-beta family signaling. J Biol Chem.2003;278(30);27853-27863.
Long J, Wang G, He D, et al. Repression of Smadl transcriptional activity by SUMO modification. Biochem J, 2004;379(1):23-29.
Liang M, Melchior F. Feng XH, et al. Regulation of Smadl sumoylation and transforming growth factor-beta signaling by protein inhibitor of activated ST ATI. J Biol Chem, 2004; 279 (22):22857-22865.
Lin X, Liang M, Liang YY, et al. Activation of transforming growth factor-beta signaling by SUMOl modification of tumor suppressor Smad4/DPC4. J Biol Client. 2003; 278( 21 ); 18714- 18719.
Khodzhigorova A, Distler A, Lang V, et al. Inhibition of sumoylation prevents experimental fibrosis. Ann Rheum Dis. 2012;71(11);1904-1908.
Netherton SJ, Bonni S. Suppression of TGFp-induced epithelial- mesenchymal transition like phenotype by a PIAS1 regulated sumoylation pathway in NMuMG epithelial cells. PLoS One, 2010; 5 (11); el3971. doi: 10. 1371/journal, pone. 0013971.
Refbacks
- There are currently no refbacks.
